Skip to content

Antisense Compounds Targeting Leucine-Rich Repeat Kinase 2(LRRK2) for the Treatment of Parkinson’s Disease

Using ASO compounds to regulate the LRRK2 transcript and partially or fully restore LRRK2 function

Published: 4th May 2022
Antisense Compounds Targeting Leucine-Rich Repeat Kinase 2(LRRK2) for the Treatment of Parkinson’s Disease
Kateryna_Kon, https://stock.adobe.com/uk/179073118, stock.adobe.com
IP Status
  • Patented
Seeking
  • Development partner
  • Licensing